These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 30182153)

  • 1. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
    Rai N; Veeroju S; Schymura Y; Janssen W; Wietelmann A; Kojonazarov B; Weissmann N; Stasch JP; Ghofrani HA; Seeger W; Schermuly RT; Novoyatleva T
    Biomed Res Int; 2018; 2018():3293584. PubMed ID: 29511676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
    Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
    Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics.
    Darocha S; Banaszkiewicz M; Pietrasik A; Piłka M; Florczyk M; Wieteska M; Dobosiewicz A; Szmit S; Torbicki A; Kurzyna M
    Int J Cardiol; 2018 Oct; 269():283-288. PubMed ID: 30017517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
    McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
    BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology.
    Badagliacca R; Poscia R; Pezzuto B; Nocioni M; Mezzapesa M; Francone M; Giannetta E; Papa S; Gambardella C; Sciomer S; Volterrani M; Fedele F; Dario Vizza C
    J Heart Lung Transplant; 2015 Mar; 34(3):395-403. PubMed ID: 25499139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
    Poch DS
    BMC Pulm Med; 2016 May; 16(1):82. PubMed ID: 27193179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension.
    Badagliacca R; Poscia R; Pezzuto B; Papa S; Pesce F; Manzi G; Giannetta E; Raineri C; Schina M; Sciomer S; Parola D; Francone M; Carbone I; Fedele F; Vizza CD
    J Heart Lung Transplant; 2016 Nov; 35(11):1321-1329. PubMed ID: 27241861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
    Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
    Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.
    Baughman RP; Shlobin OA; Gupta R; Engel PJ; Stewart JI; Lower EE; Rahaghi FF; Zeigler J; Nathan SD
    Chest; 2022 Feb; 161(2):448-457. PubMed ID: 34363816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study.
    Ahmadi A; Thornhill RE; Pena E; Renaud JM; Promislow S; Chandy G; Davies RA; Stewart DJ; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Beanlands RS; deKemp RA; Mielniczuk LM
    Can J Cardiol; 2018 Sep; 34(9):1137-1144. PubMed ID: 30170668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
    Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
    Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension.
    Badagliacca R; Raina A; Ghio S; D'Alto M; Confalonieri M; Correale M; Corda M; Paciocco G; Lombardi C; Mulè M; Poscia R; Scelsi L; Argiento P; Sciomer S; Benza RL; Vizza CD
    J Heart Lung Transplant; 2018 Mar; 37(3):365-375. PubMed ID: 28912026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat for the treatment of pulmonary arterial hypertension.
    Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
    N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
    Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.